deaths (OS)progression or deaths (PFS)RFS/DFS

limited stage SCLC (ls-SCLC) - maintenance (M) limited stage SCLC (ls-SCLC) limited stage SCLC (ls-SCLC) - maintenance (M)

versus no additional treatment
nivolumab plus ipilimumab vs. no additional treatment 1 certainty unassessable-5% certainty unassessable+2%-